SCM
VIR icon

Sterling Capital Management’s Vir Biotechnology VIR Stock Holding History

Sterling Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.2K Sell
2,477
-616
-20% -$5.86K ﹤0.01% 1783
2026
Q1 		$27.7K Sell
3,093
-2,040
-40% -$16.3K ﹤0.01% 1871
2025
Q4 		$31K Sell
5,133
-1,012
-16% -$6.03K ﹤0.01% 2001
2025
Q3 		$35.1K Buy
6,145
+3,712
+153% +$19K ﹤0.01% 1895
2025
Q2 		$12.3K Buy
2,433
+867
+55% +$4.65K ﹤0.01% 1999
2025
Q1 		$10.1K Sell
1,566
-1,302
-45% -$11.6K ﹤0.01% 1859
2024
Q4 		$21.1K Buy
2,868
+2,549
+799% +$20.1K ﹤0.01% 1856
2024
Q3 		$2.39K Buy
+319
New +$2.77K ﹤0.01% 2103

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Sterling Capital Management's VIR Position: Q2 2026 in Review

Sterling Capital Management reduced its Vir Biotechnology (VIR) stake by 20% in Q2 2026, selling an estimated $5.86K and leaving 2,477 shares worth $25.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1783.

Sterling Capital Management first reported a position in VIR in Q3 2024 and has held it in 8 quarters since. The position peaked at $35.1K in Q3 2025. 238 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Sterling Capital Management held 2,477 shares of Vir Biotechnology worth $25.2K as of Q2 2026.
  • Sterling Capital Management sold 616 Vir Biotechnology shares in Q2 2026, an estimated $5.86K.
  • Vir Biotechnology made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1783 holding.
  • Sterling Capital Management first reported a position in Vir Biotechnology in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Vir Biotechnology position peaked at $35.1K in Q3 2025.
  • 238 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.